Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Oncology Report

• Publication date

  2007-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/OR.17.4.823PMID 17342322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells.

  2005cited by this paper
• Aspirin inhibits NF-kappaB activation in a glycolysis-depleted lung epithelial cell line.

  2005cited by this paper
• Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

  2005cited by this paper
• Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.

  2005cited by this paper
• The Combination of the Selective Cyclooxygenase‐2 Inhibitor Celecoxib with Weekly Paclitaxel Is a Safe and Active Second‐Line Therapy for Non‐Small Cell Lung Cancer: A Phase II Study with Biological Correlates

  2005cited by this paper
• Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations

  2005cited by this paper
• Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial.

  2005cited by this paper
• Activation of the caspase-8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer.

  2005cited by this paper
• Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro.

  2005cited by this paper
• Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin

  2005cited by this paper
• Evidence for colorectal cancer cell specificity of aspirin effects on NFκB signalling and apoptosis

  2004cited by this paper
• Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target

  2004cited by this paper
• COX-2 inhibition and lung cancer.

  2004cited by this paper
• Cyclooxygenase as a Target in Lung Cancer

  2004cited by this paper
• Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.

  2004cited by this paper
• Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

  2004cited by this paper
• Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.

  2004cited by this paper
• Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.

  2004cited by this paper
• Celecoxib activates a novel mitochondrial apoptosis signaling pathway

  2003cited by this paper
• Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells

  2003cited by this paper
• A randomized trial of aspirin to prevent colorectal adenomas.

  2003cited by this paper
• Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma.

  2003cited by this paper
• A Randomized Trial of Aspirin to Prevent Colorectal Adenomas

  2003cited by this paper
• Celecoxib Induces Apoptosis by Inhibiting 3-Phosphoinositide-dependent Protein Kinase-1 Activity in the Human Colon Cancer HT-29 Cell Line*

  2002cited by this paper
• Regular aspirin use and lung cancer risk

  2002cited by this paper
• Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells.

  2001cited by this paper
• Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.

  2001cited by this paper
• Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.

  2001cited by this paper
• Celecoxib loses its anti‐inflammatory efficacy at high doses through activation of NF‐κB

  2001cited by this paper
• Sulindac inhibits activation of the NF-kappaB pathway.

  1999cited by this paper
• The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta.

  1998cited by this paper
• Aspirin and the risk of colorectal cancer in women.

  1996cited by this paper
• Aspirin and the risk of colorectal cancer in women.

  1995cited by this paper
• Inhibition of NF-kappa B by sodium salicylate and aspirin.

  1994cited by this paper

• Aspirin in Cancer Therapy: Pharmacology and Nanotechnology Advances

  2025cites this paper
• Identification of key genes and long non-coding RNAs in celecoxib-treated lung squamous cell carcinoma cell line by RNA-sequencing

  2018cites this paper
• NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization.

  2016cites this paper
• Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets.

  2016cites this paper
• Molecular docking studies on interaction of Annona muricata compounds with antiapoptotic proteins Bcl-2 and survivin

  2016cites this paper
• Synthesis and Identification of New 4-Arylidene Curcumin Analogs as Potential Anticancer Agents Targeting Nuclear Factor-κB Signaling Pathway

  2014cites this paper
• Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma

  2013cites this paper
• Deubiquitinase Inhibition of 19S Regulatory Particles by 4-Arylidene Curcumin Analog AC17 Causes NF-κB Inhibition and p53 Reactivation in Human Lung Cancer Cells

  2013cites this paper
• Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNFα-induced nuclear factor-κB activation inhibition.

  2012cites this paper
• Established and novel NF-κB inhibitors lead to downregulation of TLR3 and the proliferation and cytokine secretion in HNSCC.

  2011cites this paper
• Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.

  2010cites this paper
• Targeting the eicosanoid pathway in non-small-cell lung cancer

  2009cites this paper
• Nuclear Factor-κB and Chemoresistance: How Intertwined Are They?

  2009cites this paper
• Celecoxib plays a multiple role to peripheral blood lymphocytes and allografts in acute rejection in rats after cardiac transplantation

  2009cites this paper
• Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma.

  2009cites this paper
• Cyclooxygenase 2 and its Metabolites: Implications for Lung Cancer Therapy

  2009cites this paper
• Apoptosis in Carcinogenesis and Chemotherapy

  2009cites this paper
• Chronic obstructive pulmonary disease and lung cancer: inflammation, the missing link

  2009cites this paper
• Celecoxib transiently inhibits cellular protein synthesis.

  2008cites this paper
• Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy.

  2008cites this paper
• Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications.

  2007cites this paper
• Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt

  2007cites this paper
• Pubblicazioni censiteAnno 2006 Linea 1: Prevenzione e cura della disabilità e management geriatrico: modelli organizzativi e gestionali e verifica della qualità dei servizi per gli Anziani

  2006cites this paper